Human Papillomavirus (HPV) – Cannabis Research

Description of Human Papillomavirus (HPV)

Human papillomavirus (HPV) is one of the most common viral infections worldwide, with over 200 known types that primarily infect epithelial tissues of the skin and mucous membranes. Transmission occurs mainly through direct skin-to-skin or sexual contact. While most HPV infections are transient and cleared by the immune system within one to two years, certain strains can persist and lead to disease.

HPV types are generally categorized into low-risk and high-risk groups:

• Low-risk HPV types (such as HPV-6 and HPV-11) are not associated with cancer but can cause benign growths. The most common are anogenital warts (condylomata acuminata) and recurrent respiratory papillomatosis, a rare condition where warts grow in the respiratory tract, sometimes obstructing airflow.


• High-risk HPV types (particularly HPV-16 and HPV-18, but also several others like 31, 33, and 45) are strongly linked to the development of cancers. These viruses can integrate into host cell DNA, disrupting normal cell-cycle regulation and leading to uncontrolled growth.

The most significant conditions caused by persistent high-risk HPV infection include:

• Cervical cancer – nearly all cases are attributable to HPV, making it the leading HPV-related malignancy worldwide.


• Other anogenital cancers – HPV is implicated in cancers of the vulva, vagina, penis, and anus.


• Oropharyngeal cancers – particularly cancers of the tonsils and base of tongue, which have been rising in incidence, especially in men.

Importantly, HPV infection is often asymptomatic, meaning individuals may unknowingly transmit the virus. Preventive strategies are therefore crucial. Regular cervical screening (Pap tests, HPV testing) remains a cornerstone in reducing cancer incidence and mortality, as early detection of precancerous changes allows for effective intervention.

HPV vaccination has been in the news recently, sparking debate between proponents and critics. Advocates point to robust evidence of reduced HPV infections, precancerous lesions, and related cancers in populations with high vaccination rates. Opponents, meanwhile, raise concerns about potential side effects, long-term safety data, and the balance of individual choice versus public health goals. Both sides draw on scientific studies and expert commentary, underscoring the ongoing need for transparent communication and continued research.